RxDoctor Payments Data

Alice Johnson

Community Health · Detroit, MINPI 1558615419

Payments from drug & device makers

$8,291in general payments, 2019–2025

Across 303 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$2K
  • Merck$617
  • Johnson & Johnson$501
  • Janssen Products, LP$219
  • AbbVie$151
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$350%
  • Food & beverage$8,05797%
  • Education$1992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few community health providers in Michiganto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala131$508,636
OdefseyEmtricitab/Rilpiviri/Tenof Ala48$168,172
JulucaDolutegravir/Rilpivirine35$122,875
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf18$82,411
DovatoDolutegravir Sodium/Lamivudine16$44,340
TivicayDolutegravir Sodium19$43,836
DelstrigoDoravirine/Lamivu/Tenofov Diso11$27,710
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med21$314
Potassium Chloride17$99
Gabapentin14$75
Atorvastatin Calcium14$52
Amlodipine Besylate35$43
Hydrochlorothiazide15$21
Simvastatin11$6

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$2,281$508,636131 claims
Viiv Healthcare CompanyJuluca, Dovato, Tivicay$3,206$211,05170 claims
Janssen Products, LPSymtuza$219$82,41118 claims
MerckDelstrigo$617$27,71011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few community health providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other community health in Detroit

Where these figures come from

Is this you, or does something look wrong? →